---

**From:** Alan Perkins <jon82@example.net>  
**To:** Edward Pruitt <haysbrittany@example.net>  
**Subject:** Follow-up on Phase II Clinical Trial Data  

Hi Edward,

I hope this message finds you well. I'm reaching out regarding the ongoing Phase II clinical trial data for MK-7621. We need to align on the preliminary outcomes to ensure that the data is consistent with our expectations before the submission deadline on November 15th.

Could we schedule a time this week to go over the latest results and any potential discrepancies you've observed? I am particularly interested in your insights on the pharmacokinetic profiles we discussed in our last meeting. Let me know your availability; I'm free Thursday or Friday morning.

Also, just a heads-up, I'll be on leave starting November 20th for a week, so I'll need to wrap up any outstanding issues before then.

Looking forward to your feedback.

Best,  
Alan Perkins  
Clinical Research Associate  
Merck & Co.  
Phone: (732) 555-0145  

---

**From:** Edward Pruitt <haysbrittany@example.net>  
**To:** Alan Perkins <jon82@example.net>  
**Subject:** Re: Follow-up on Phase II Clinical Trial Data  

Hi Alan,

Thanks for reaching out. I've been reviewing the data sets, and I've noticed some variations in the bioavailability metrics across different cohorts that we should discuss. It would be ideal to address these before the submission.

I'm available Thursday at 10 AM. Does that work for you? We can meet in Conference Room B on the third floor. I'll bring the latest data sheets and my analysis notes.

I'll make sure we have everything in order before your leave. Enjoy your time off! Let me know if there's anything specific you want me to handle while you're away.

Best regards,  
Edward Pruitt  
Scientist, Product/Process Development  
Merck & Co.  
Office: (732) 555-0193  

---